女性診斷檢查市場

女性診斷檢查市場 是由出版商Trimark Publications在2010年06月所出版的。 這份英文市場調查報告書包含187 Pages 價格從美金3400起跳。

簡介

本報告，針對女性診斷檢查的各種裝置、試劑、供應等的市場進行調查分析，並彙整區域/國家・檢查裝置・機器類型別的市場規模實績・預測、製造業者的市佔率、各種市場影響因素、產業動向、技術動向、主要企業的檔案資料等，由下列摘要形式闡述。

封面圖片：

第1章 概要

第2章 簡介

• 全球的診斷產品產業

第3章 女性診斷檢查市場的分析：市場規模・成長率・市佔率

• 全球市場
• 美國市場
• 歐洲市場
• 日本市場
• 中國市場
• 其他區域

第4章 女性診斷檢查：個別市場

• 懷孕檢查
• 骨質疏鬆症檢查
• 產前篩選検査
• 生育檢查
• 乳癌
• 卵巢癌
• 子宮頸癌
• 其他檢查
• HIV
• 感染症檢查
• 嬰兒黃疸檢查

第5章 全球的乳腺X光攝影檢查市場

• 乳腺X光攝影檢查的概要
• 市場概要
• 市場機會
• 市場分析
• 策略性展望
• 膠捲的乳腺X光攝影檢查市場
• 數位乳腺X光攝影檢查市場

第6章 女性診斷檢查：成長影響因素

• 成長的影響因素
• 個人接受度
• 主要人物
• 主要因素
• 補助
• 病患身邊所進行的快速檢查
• 附屬設施
• 實驗照護的區域化
• 女性診斷檢查的必要條件
• CLIA（Clinical Laboratory Improvement Act of 1988），等

第7章 產業的商業動向

• 部門整合
• 診斷檢查的成長動向
• 收購・執照合約・內部發展・合作
• 產品檢查的深度
• 政府的法規
• 普及率的擴大
• 法規課題，等

第8章 重要技術動向

第9章 企業檔案資料

第10章 附錄

圖表

目錄

Abstract

The purpose of this TriMark Publications report is to describe the specific segment of the in vitro diagnostics (IVDs) market called women' s health testing. This study includes contemporary and generally accepted clinical and analytical activities. This analysis examines clinical measurement devices, as well as their reagents and supplies, as utilized in hospitals, clinics and doctor' s offices. Some diagnostic tests, which are marketed primarily as over-the-counter products, are included in this report. This report also includes other important tests like mammography, (i.e., tests which are not generally associated with IVD tests, but which are an important component of the overall women' s health market). This study deals with analysis related to the common chemical constituents of blood, plasma or serum of concern to patient testing in the field of women' s health. Emphasis is on those companies and products that are actively developing and marketing clinical laboratory instrumentation, reagents and supplies for performing diagnostic tests related to women' s health. This study concentrates on the women' s health testing market segment in important worldwide markets such as the U.S., Japan and Europe.

Report Statistics

• Publication Date: 01-JUN-10
• Pages: 187
• Format: PDF document

Table of Contents

1.0 Overview

• 1.1 Statement of Report
• 1.2 Scope of this Report
• 1.3 Methodology
• 1.4 Executive Summary

2.0 Introduction - Sector Overview

• 2.1 Global Diagnostic Products Industry

3.0 Women' s Health Testing Market Analysis in Size, Growth and Share

• 3.1 Global Women' s Health Testing Markets
  • 3.1.1 Market Drivers in the Women' s Health Diagnostics Testing Sector
    • 3.1.1.1 Market Segments for Women' s Health Testing
    • 3.1.1.2 Key Players in the Women' s Health Diagnostics Testing Segment
    • 3.1.1.3 Women' s Health Testing Sector Analysis
• 3.2 U.S. Women' s Health Testing Market
  • 3.2.1 Market Overview
  • 3.2.2 Diagnostic Test Categories
• 3.3 European Women' s Health Diagnostic Test Market
  • 3.3.1 German Women' s Care Diagnostic Market
  • 3.3.2 U.K. Women' s Care Testing Diagnostic Market
    • 3.3.2.1 U.K. Market Statistics
    • 3.3.2.2 U.K. Competitive Analysis
    • 3.3.2.3 U.K. Market Access
  • 3.3.3 French Care Diagnostic Market
  • 3.3.4 Italian Women' s Care Diagnostic Market
  • 3.3.5 Spanish Women' s Care Diagnostic Market
• 3.4 Japanese Women' s Care Testing Market
• 3.5 Chinese Women' s Care Market
• 3.6 Rest of the World Women' s Care Testing Market

4.0 Women' s Health Testing Individual Markets

• 4.1 Pregnancy Testing
• 4.2 Osteoporosis Testing
  • 4.2.1 In Vitro Blood Tests
  • 4.2.2 Bone Densitometry Devices
• 4.3 Prenatal Screening Testing
  • 4.3.1 Cystic Fibrosis
  • 4.3.2 Prenatal Genetic Testing
  • 4.3.3 Fragile X Syndrome
  • 4.3.4 Tay-Sachs Disease
• 4.4 Fertility Testing
• 4.5 Breast Cancer
  • 4.5.1 CA 15-3
  • 4.5.2 CA 27-29
  • 4.5.3 BRCA1 Breast and Ovarian Cancer Gene
  • 4.5.4 BRCA2 Breast Cancer Gene
  • 4.5.5 Tissue polypeptide antigen (TPA)
  • 4.5.6 DNA Ploidy and S-phase Fraction
  • 4.5.7 Estrogen and Progesterone Receptor (ER and PR)
  • 4.5.8 HER-2
  • 4.5.9 HER-2 and Herceptin
  • 4.5.10 p53
  • 4.5.11 NMP66
  • 4.5.12 Mammastatin
• 4.6 Ovarian Cancer
  • 4.6.1 CA 125 II™
  • 4.6.2 Steroid Hormone Receptors
  • 4.6.3 Epidermal Growth Factor Receptor (EGFR)
  • 4.6.4 HER-2/neu
  • 4.6.5 P53 Tumor Suppressor Gene
  • 4.6.6 Lysophospholipids
• 4.7 Cervical Cancer
  • 4.7.1 Pap Smears
  • 4.7.2 Human Papillomavirus (HPV) Testing
• 4.8 Miscellaneous Testing
  • 4.8.1 Estriol
  • 4.8.2 Fetal Fibronectin (fFN)
  • 4.8.3 Vaginal pH and Vaginitis
• 4.9 Human Immunodeficiency Virus (HIV)
• 4.10 Infectious Disease Testing
  • 4.10.1 Strep Testing
  • 4.10.2 Chlamydia
  • 4.10.3 Methicillin-Resistant Staphylococcus Aurea (MRSA)
  • 4.10.4 Hepatitis
  • 4.10.4 Gonorrhea
  • 4.10.5 Urinary Tract Infections
• 4.11 Infant Jaundice

5.0 World Mammography Market

• 5.1 Mammography Overview
• 5.2 Market Overview
  • 5.2.1 Introduction
  • 5.2.2 World Mammography Markets Revenue
  • 5.2.3 Mammography Markets by Region
  • 5.2.4 Total Market Share
  • 5.2.5 Competitive Structure
• 5.3 Market Opportunities
  • 5.3.1 Resource Management for Mammography Markets
  • 5.3.2 Movement to Higher Reimbursement Rates
  • 5.3.3 Market Benchmarks for Increased Mammography Utilization
• 5.4 Market Analysis
  • 5.4.1 Strategic Partnerships
  • 5.4.2 Long Term Trends
• 5.5 Strategic Outlook
  • 5.5.1 Competitive Elements of Mammography Markets
  • 5.5.2 Higher Reimbursement Rates
  • 5.5.3 Volume Requirements
  • 5.5.4 Product Innovation
  • 5.5.5 Product Leadership
  • 5.5.6 Product Line Strategy
  • 5.5.7 Pricing Strategy & Reimbursement
  • 5.5.8 Strategic Partnerships
• 5.6 Film-Based Mammography Market
  • 5.6.1 Market Overview
    • 5.6.1.1 Unit and Revenue Forecasts
    • 5.6.1.2 Product Analysis
  • 5.6.2 Market Drivers
  • 5.6.3 Market Restraints
  • 5.6.4 Film-Based Mammography Market and Technology Trends
  • 5.6.5 U.S. Market for Film-Based Screening Systems
    • 5.6.5.1 Unit Shipment and Revenue Forecasts
    • 5.6.5.2 Competitive Analysis
    • 5.6.5.3 U.S. Installed Base Analysis
  • 5.6.6 European Market for Film-Based Mammography Systems
    • 5.6.6.1 Unit Shipment and Revenue Forecasts
    • 5.6.6.2 Competitive Analysis
    • 5.6.6.3 Installed Base Analysis
  • 5.6.7 Japanese (Pacific Rim) Market for Film-based Mammography Systems
    • 5.6.7.2 Competitive Analysis
    • 5.6.7.3 Installed Base Analysis
  • 5.6.8 Rest of the World Market for Film-based Mammography Systems
    • 5.6.8.1 Unit Shipment and Revenue Forecasts
    • 5.6.8.2 Installed Base Analysis
• 5.7 Digital X-Ray Mammography Market
  • 5.7.1 Digital Mammography Overview
  • 5.7.2 Market Overview
  • 5.7.3 Product Background
  • 5.7.4 Product Description
  • 5.7.5 Market Drivers
  • 5.7.6 Market Restraints
  • 5.7.7 Unit Shipment and Revenue Forecasts
  • 5.7.8 Percentage Breakdown of Revenues by Region
  • 5.7.9 Market Share
  • 5.7.10 U.S. Market for Digital Mammography Systems
    • 5.7.10.1 U.S. Sales
    • 5.7.10.2 Competitive Analysis
  • 5.7.11 European Market for Digital Mammography Systems
    • 5.7.11.1 Unit Shipment and Revenue Forecasts
    • 5.7.11.2 Competitive Analysis
    • 5.7.11.3 Installed Base Analysis
  • 5.7.12 Japanese (Pacific Rim) Market for Digital Mammography Systems
    • 5.7.12.1 Unit Shipment and Revenue Forecasts
    • 5.7.12.2 Competitive Analysis
    • 5.7.12.3 Installed Base Analysis

6.0 Women' s Health Testing: Growth Regulators

• 6.1 Moderators of Growth
• 6.2 Personnel Acceptance
• 6.3 Key People for Women' s Health Testing
• 6.4 Key Elements for Women' s Health Testing
• 6.5 Women' s Health Testing and Reimbursement
• 6.6 Rapid Near-Patient Testing in Hospitals
• 6.7 Satellite Facilities
• 6.8 Regionalization of Laboratory Care
• 6.9 Requirements for Women' s Health Testing
• 6.10 Clinical Laboratory Improvement Act of 1988 (CLIA)

7.0 Business Trends in the Industry

• 7.1 Sector Consolidation
• 7.2 Diagnostic Testing Growth Trends
• 7.3 Acquisition, License Agreements, Internal Development and Partnerships
• 7.4 Product Testing Depth in Women' s Health Testing
• 7.5 Government Regulation
  • 7.5.1 U.S. Regulation
    • 7.5.1.1 Importing Medical Devices into the U.S.
    • 7.5.1.2 Exporting Medical Devices from the U.S.
  • 7.5.2 U.K. Regulation
  • 7.5.3 E.U. Regulation
  • 7.5.4 Japanese Regulation
• 7.6 Increased Market Penetration
• 7.7 Legal Issues

8.0 Important Technology Trends

9.0 Company Profiles

• 9.1 Abbott Diagnostics
• 9.2 Accurex Biomedical, Pvt., Ltd
• 9.3 Adeza Biomedical Corporation (Acquired by Hologic)
• 9.4 Agfa-Gevaert Corporation
• 9.5 Ambri Ltd.
• 9.6 American Biomedica Corp. (ABMC)
• 9.7 Analogic Corporation
• 9.8 Axis-Shield Plc.
• 9.9 Becton Dickinson (BD)
• 9.10 Biomerica, Inc.
• 9.11 Capintec, Inc.
• 9.12 Carestream Health, Inc.
• 9.13 CMT Medical Technologies Ltd.
• 9.14 Concateno Plc.
• 9.15 Dalsa Corp.
• 9.16 Denka Seiken Co., Ltd.
• 9.17 DiaDexus, Inc.
• 9.18 Dilon Diagnostics
• 9.19 FujiFilm Medical Systems USA
• 9.20 General Electric Healthcare
• 9.21 Genzyme Corp.
• 9.22 Hologic Inc.
• 9.23 iCAD, Inc.
• 9.24 Imaging Diagnostic Systems, Inc.
• 9.25 Inverness Medical Innovations, Inc. (Alere)
• 9.26 Invivo Corp.
• 9.27 Johnson & Johnson, Inc.
• 9.28 Kyowa Medex Co., Ltd.
• 9.29 Lantheus Medical Imaging, Inc.
• 9.30 LifeScan Corporation
• 9.31 Matritech (Acquired by Inverness Medical Innovations)
• 9.32 Medix Biochemica
• 9.33 Mitsubishi Kagaku Iatron
• 9.34 Myraid Genetics, Inc.
• 9.35 OraSure Technologies, Inc.
• 9.36 Polymedco, Inc.
• 9.37 Procrea Cliniques
• 9.38 QIAGEN in USA
• 9.39 Quest Diagnostics, Inc.
• 9.40 Quidel Corp.
• 9.41 Rad-Icon Imaging Corp
• 9.42 Roche Ltd.
• 9.43 Scanis Inc.
• 9.44 Sectra Imtec AB
• 9.45 Shanghai Kehua Bioengineering Co., Ltd.
• 9.46 Siemens Medical Solutions USA, Inc.
• 9.47 Vidar Systems Corp.

10.0 Appendices

• 10.1 Digital Database for Screening Mammography (DDSM)
• 10.2 Sources of National Cancer Institute Information
• 10.3 Screening Mammograms: Questions and Answers
• 10.4 FDA Rule: State Certification of Mammography Facilities

INDEX OF TABLES

• Table 2.1: Worldwide Market Share In Vitro Diagnostic Companies
• Table 2.2: Worldwide In Vitro Diagnostics Market Size, 2001-2012
• Table 2.3: Worldwide In Vitro Clinical Laboratory Diagnostic Testing 2003-2012
• Table 2.4: Worldwide Point-of-Care Diagnostic Testing 2001-2012
• Table 3.1: Top Drugstore Retailers in the U.S.
• Table 3.2: Top Drugstore Wholesalers in the U.S.
• Table 3.3: U.S. Women' s Health Diagnostics Products Market Sales 2000-2012
• Table 3.4: Regional Comparison Healthcare and IVD
• Table 3.5: European Women' s Care Testing Market, 2000-2012
• Table 3.6: European Women' s Care Testing Diagnostics Market
• Table 3.7: German Women' s Care Testing Diagnostics Products Market Sales, 2000-2012
• Table 3.8: German Patient Care Laboratory Test Market, 2000-2012
• Table 3.9: German Alternate Site Testing Market, 2000-2012
• Table 3.10: German Hospital Point of Care Market, 2000-2012
• Table 3.11: German Clinical Diagnostic Rapid Women' s Test Market Segments
• Table 3.12: U.K. Women' s Health Diagnostics Products Market Sales, 2006-2012
• Table 3.13: Major U.K. IVD Manufacturers
• Table 3.14: U.S. IVD Manufacturers Doing Business in the U.K.
• Table 3.15: Other European Companies that Manufacture IVD Products in the U.K.
• Table 3.16: French Women' s Health Diagnostics Products Market Sales, 2000-2012
• Table 3.17: Italian Women' s Health Diagnostics Products Market Sales, 2000-2012
• Table 3.18: Spanish Women' s Heath Diagnostics Products Market Sales, 2000-2012
• Table 3.19: Japan Women' s Care Testing Market, 2000-2012
• Table 3.20: Chinese Women' s Care Diagnostics Products Market Sales, 2000-2012
• Table 3.21: ROW Women' s Care Testing Market, 2000-2012
• Table 4.1: U.S. Women' s Health Testing Pregnancy Testing Market, 2001-2012
• Table 4.2: U.S. Market Share for Rapid Women' s Health Testing Pregnancy Tests
• Table 4.3: Pregnancy Test Market for OTC Testing in the U.S., 2000-2012
• Table 4.4: Home Pregnancy Tests Available in the U.S. Market
• Table 4.5: Osteoporosis Risk Factors that Cannot Be Changed
• Table 4.6: Osteoporosis Risk Factors that Can Be Changed
• Table 4.7: Prenatal Screening Types
• Table 4.8: History: Parental Genetic Traits
• Table 4.9: Female Factor Infertility
• Table 4.10: Frequency of Mutation Based Upon Ethnicity
• Table 4.11: Reasons for CF Testing
• Table 4.12: CF Testing Methodology
• Table 4.13: CF Gene Detection Rates Vary by Ethnic Background
• Table 4.14: Global Market for CF Diagnostic Testing, 2000-2012
• Table 4.15: U.S. Market for CF Diagnostic Testing, 2000-2012
• Table 4.16: Commercial CF Screening Products
• Table 4.17: Emerging CF Screening Products
• Table 4.18: CF Screening Technology Summary
• Table 4.19: Genetic Screening During Pregnancy
• Table 4.20: Ultrasound Screening
• Table 4.21: Future Trends in Prenatal Genetic Testing, 2000-2012
• Table 4.22: Ovulation Predictors
• Table 4.23: TPA Marker Sensitivity
• Table 4.24: HPV Risk Factors
• Table 4.25: Relationship between HPV and Cervical Carcinoma
• Table 4.26: HPV and Cervical Carcinoma Risk
• Table 4.27: Rationale for Reflex HPV Testing with Cytology
• Table 4.28: Rationale against Reflex HPV Testing with Cytology
• Table 4.29: Predictability of HPV Test by Abnormal Pap Smear Type
• Table 4.30: Incidence of Cervical Cancer and Cytological Abnormalitie
• Table 4.31: Long Term Trends in HPV Testing
• Table 4.32: U.S. Women' s Health Testing Market for HIV, 2001-2012
• Table 4.33: Countries with the Highest Prevalence of HIV / AIDS
• Table 4.34: U.S. Strep Testing Market Size, 2002-2012
• Table 4.35: U.S. Market for Rapid Point of Care Strep Tests
• Table 4.36: U.S. Chlamydia Testing Market, 2000-2012
• Table 4.37: Summary of Hepatitis Test Technology
• Table 5.1: U.S. Healthcare Expenditures, 2000-2010
• Table 5.2: International Per Capita Healthcare Spending by Country, 2007
• Table 5.3: U.S. Use of Mammography in Women Over 40, 1987-2008
• Table 5.4: Annual Mammography Procedures in the U.S., 2000-2008
• Table 5.5: Annual Mammography Procedures in Europe, 2002-2008
• Table 5.6: Annual Mammography Procedures in Japan, 2002-2008
• Table 5.7: Annual Mammography Procedures in the Rest of the World, 2002-2008
• Table 5.8: U.S. Mammography Facts, 2008
• Table 5.9: Breast Cancer Survival Rates by Country
• Table 5.10: Surgical Biopsies Performed in the U.S., 2000-2009
• Table 5.11: Worldwide Mammography Instrument Market, 2000-2010
• Table 5.12: Worldwide Mammography Instrumentation Placements, 2002-2010
• Table 5.13: Worldwide Film-Based Mammography Instrumentation Placements, 2002-2010
• Table 5.14: Worldwide Mammography Film-Based Instrument Market, 2000-2010
• Table 5.15: Worldwide Mammography Film-Based Instrument Market by Region, 2000-2010
• Table 5.16: U.S. Mammography Film-Based Instrument Market, 2000-2010
• Table 5.17: U.S. Mammography Film-Based Instrument Market Manufacturer Share
• Table 5.18: U.S. Film-Based Mammography Instrumentation Placements, 2002-2010
• Table 5.19: European Mammography Film-Based Instrument Market, 2000-2010
• Table 5.20: European Film-Based Mammography Instrumentation Placements, 2002-2010
• Table 5.21: European Mammography Film-Based Instrument Market Manufacturer Share
• Table 5.22: Japanese Mammography Film-Based Instrument Market, 2000-2010
• Table 5.23: Japanese Film-Based Mammography Instrumentation Placements, 2002-2010
• Table 5.24: Japanese Mammography Film-Based Instrument Market Manufacturer Share
• Table 5.25: ROW Mammography Film-Based Instrument Market, 2000-2010
• Table 5.26: ROW Film-Based Mammography Instrumentation Placements, 2002-2010
• Table 5.27: Advantages of Digital Mammography
• Table 5.28: Worldwide Digital General Radiography Market, 2000-2012
• Table 5.29: Worldwide Market for Digital Mammography Systems Annual Unit Sales, 2000-2010
• Table 5.30: Worldwide Market for Digital Mammography Systems, 2000-2010
• Table 5.31: Worldwide Mammography Digital Instrumentation Placements, 2002-2010
• Table 5.32: Worldwide Mammography Digital Instrument Market by Region, 2001-2010
• Table 5.33: Share of Worldwide Market for Digital Mammography Systems by Competitor
• Table 5.34: U.S. Mammography Digital Instrument Market, 2001-2010
• Table 5.35: U.S. Digital Mammography Instrumentation Placements, 2002-2010
• Table 5.36: European Mammography Digital Instrument Market, 2001-2010
• Table 5.37: European Digital Mammography Instrumentation Placements, 2002-2010
• Table 5.38: Japanese Mammography Digital Instrument Market, 2001-2010
• Table 5.39: Japanese Digital Mammography Instrumentation Placements, 2002-2010
• Table 9.1: Products Marketed By Abbott in the Diagnostic Market

相關商品

體外診斷設備相關市場調查報告書

全球切片設備市場:開發平台分析，競爭環境，到2018年為止的市場預測
Biopsy Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018
價格 : US $ 3995
出版日期 : 2012年04月

全球分子診斷市場:各國的設施·檢驗數量·銷售額預測
2012 World Molecular Diagnostics Market Overview: Facilities, Test Volumes, and Sales Forecasts by Country
價格 : US $ 1850
出版日期 : 2012年04月

全球微生物測試市場展望：成長機會及業務拓展策略
2012 Microbiology Testing Market Outlook: Growth Opportunities and Strategies
價格 : US $ 28700
出版日期 : 2012年04月

Trimark Publications發行的醫療設備相關市場調查報告書

個人化醫療與癌症治療上的搭配診斷

Companion Diagnostics in Personalized Medicine and Cancer Therapy

價格 : US $ 3400

出版日期 : 2012年02月

血糖值檢驗及糖尿病管理

Blood Glucose Testing and Diabetes Management

價格 : US $ 3400

出版日期 : 2012年02月

全球醫護站診斷檢驗市場

Point of Care Diagnostic Testing World Markets

價格 : US $ 3400

出版日期 : 2012年02月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!